Clinical Trial Update: High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating high-dose PEG-Intron in patients with melanoma completed; results were posted in 2013. The study assessed the pharmacok…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2013-07-31